Identification of distinct pathological signatures induced by patient-derived α-synuclein structures in nonhuman primates.


Journal

Science advances
ISSN: 2375-2548
Titre abrégé: Sci Adv
Pays: United States
ID NLM: 101653440

Informations de publication

Date de publication:
05 2020
Historique:
received: 21 10 2019
accepted: 06 03 2020
entrez: 20 5 2020
pubmed: 20 5 2020
medline: 9 4 2022
Statut: epublish

Résumé

Dopaminergic neuronal cell death, associated with intracellular α-synuclein (α-syn)-rich protein aggregates [termed "Lewy bodies" (LBs)], is a well-established characteristic of Parkinson's disease (PD). Much evidence, accumulated from multiple experimental models, has suggested that α-syn plays a role in PD pathogenesis, not only as a trigger of pathology but also as a mediator of disease progression through pathological spreading. Here, we have used a machine learning-based approach to identify unique signatures of neurodegeneration in monkeys induced by distinct α-syn pathogenic structures derived from patients with PD. Unexpectedly, our results show that, in nonhuman primates, a small amount of singular α-syn aggregates is as toxic as larger amyloid fibrils present in the LBs, thus reinforcing the need for preclinical research in this species. Furthermore, our results provide evidence supporting the true multifactorial nature of PD, as multiple causes can induce a similar outcome regarding dopaminergic neurodegeneration.

Identifiants

pubmed: 32426502
doi: 10.1126/sciadv.aaz9165
pii: aaz9165
pmc: PMC7220339
doi:

Substances chimiques

Amyloid 0
alpha-Synuclein 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

eaaz9165

Informations de copyright

Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC).

Références

Nucleic Acids Res. 2010 Sep;38(17):e169
pubmed: 20660011
Nature. 2017 Feb 2;542(7639):115-118
pubmed: 28117445
Nat Commun. 2019 Mar 7;10(1):973
pubmed: 30846695
Nat Neurosci. 2020 Jan;23(1):21-31
pubmed: 31792467
Behaviour. 1974;49(3):227-67
pubmed: 4597405
J Biol Chem. 2019 Jul 5;294(27):10392-10406
pubmed: 31142553
Trends Neurosci. 1989 Oct;12(10):366-75
pubmed: 2479133
Brain. 2019 Nov 1;142(11):3565-3579
pubmed: 31580415
Proc Natl Acad Sci U S A. 2011 Mar 8;108(10):4194-9
pubmed: 21325059
Elife. 2018 Jul 03;7:
pubmed: 29969391
Sci Transl Med. 2010 Apr 21;2(28):28ra28
pubmed: 20410529
Acta Neuropathol. 2017 Dec;134(6):819-838
pubmed: 28803412
Nature. 2016 Oct 05;538(7623):20-23
pubmed: 27708329
Clin Chem. 2009 Apr;55(4):611-22
pubmed: 19246619
Acta Neuropathol Commun. 2015 Jul 25;3:46
pubmed: 26205255
Brain. 1991 Aug;114 ( Pt 4):1953-75
pubmed: 1832073
J Neuropathol Exp Neurol. 2004 Dec;63(12):1225-35
pubmed: 15624759
Nat Rev Neurosci. 2017 Jan 20;18(2):101-113
pubmed: 28104909
J Neurosci. 2010 Sep 15;30(37):12535-44
pubmed: 20844148
Science. 2012 Nov 16;338(6109):949-53
pubmed: 23161999
Eur J Pharmacol. 2015 Jul 15;759:118-26
pubmed: 25841877
Ann Neurol. 2014 Mar;75(3):351-62
pubmed: 24243558
Neurobiol Dis. 2015 Jul;79:81-99
pubmed: 25937088
Nat Med. 2015 Dec;21(12):1406-15
pubmed: 26646497
Mov Disord. 2016 Feb;31(2):161-8
pubmed: 26347034
Mov Disord. 2012 Oct;27(12):1478-83
pubmed: 23008164
Neurobiol Aging. 2003 Mar-Apr;24(2):197-211
pubmed: 12498954
Exp Neurol. 2004 Sep;189(1):1-4
pubmed: 15296829
Protein Sci. 2004 Dec;13(12):3314-21
pubmed: 15537750
PLoS One. 2013 Jul 04;8(7):e67711
pubmed: 23861787
Trends Neurosci. 2019 Jan;42(1):4-13
pubmed: 30342839
Front Behav Neurosci. 2014 Feb 19;8:47
pubmed: 24600363
Nat Struct Mol Biol. 2016 May;23(5):409-15
pubmed: 27018801
Nat Commun. 2013;4:2575
pubmed: 24108358
Nat Med. 2017 Feb 7;23(2):1-13
pubmed: 28170377
Nat Med. 2008 May;14(5):501-3
pubmed: 18391963
Neurosci Lett. 2009 Apr 3;453(2):77-80
pubmed: 19356597
J Biol Chem. 2012 Sep 28;287(40):33691-705
pubmed: 22843695
Acta Neuropathol. 2003 Jul;106(1):83-8
pubmed: 12687392
Prog Neurobiol. 2017 Aug;155:171-193
pubmed: 26209472
Nature. 2015 Jun 18;522(7556):340-4
pubmed: 26061766
Parkinsonism Relat Disord. 2012 Jan;18 Suppl 1:S210-2
pubmed: 22166438
Sci Rep. 2017 Jun 20;7(1):3902
pubmed: 28634347
Brain Res. 2009 Aug 25;1286:208-14
pubmed: 19559009
Nat Struct Mol Biol. 2019 Nov;26(11):1044-1052
pubmed: 31695184
Nature. 2015 Sep 24;525(7570):486-90
pubmed: 26352473
Nat Commun. 2019 Dec 4;10(1):5535
pubmed: 31797870
J Neurosci. 2001 Sep 1;21(17):6853-61
pubmed: 11517273
Nat Med. 2008 May;14(5):504-6
pubmed: 18391962
PLoS One. 2013 Apr 29;8(4):e62141
pubmed: 23658620
Hum Mol Genet. 2014 Jun 1;23(11):2802-15
pubmed: 24399444
Cell Res. 2018 Sep;28(9):897-903
pubmed: 30065316
Nat Med. 2008 May;14(5):507-9
pubmed: 18391961
Hum Mol Genet. 2017 Jul 15;26(14):2603-2615
pubmed: 28520872

Auteurs

M Bourdenx (M)

Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France.
CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France.

A Nioche (A)

Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France.
CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France.
Institut Jean Nicod, Département d'études cognitives, ENS, EHESS, PSL Research University, 75005 Paris, France.
Institut Jean Nicod, Département d'études cognitives, CNRS, UMR 8129, Paris, France.

S Dovero (S)

Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France.
CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France.

M-L Arotcarena (ML)

Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France.
CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France.

S Camus (S)

Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France.
CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France.

G Porras (G)

Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France.
CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France.

M-L Thiolat (ML)

Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France.
CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France.

N P Rougier (NP)

Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France.
CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France.
INRIA Bordeaux Sud-Ouest, 33405 Talence, France.

A Prigent (A)

INSERM, U1235, Nantes F-44035, France.
Nantes University, Nantes F-44035, France.
CHU Nantes, Department of Neurology, Nantes F-44093, France.

P Aubert (P)

INSERM, U1235, Nantes F-44035, France.
Nantes University, Nantes F-44035, France.
CHU Nantes, Department of Neurology, Nantes F-44093, France.

S Bohic (S)

EA-7442 Rayonnement Synchrotron et Recherche Medicale, RSRM, University of Grenoble Alpes, 38000 Grenoble, France.

C Sandt (C)

SMIS beamline, Synchrotron SOLEIL, l'orme des merisiers, 91192 Gif sur Yvette, France.

F Laferrière (F)

Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France.
CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France.

E Doudnikoff (E)

Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France.
CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France.

N Kruse (N)

Paracelsus-Elena-Klinik, Kassel, Germany.
University Medical Center Goettingen, Institute of Neuropathology, Goettingen, Germany.

B Mollenhauer (B)

Paracelsus-Elena-Klinik, Kassel, Germany.
University Medical Center Goettingen, Institute of Neuropathology, Goettingen, Germany.

S Novello (S)

Department of Medical Sciences, Section of Pharmacology, University of Ferrara, via Fossato di Mortara 17-19, 44121 Ferrara, Italy.
Neuroscience Center and National Institute of Neuroscience, University of Ferrara, via Fossato di Mortara 17-19, 44121 Ferrara, Italy.

M Morari (M)

Department of Medical Sciences, Section of Pharmacology, University of Ferrara, via Fossato di Mortara 17-19, 44121 Ferrara, Italy.
Neuroscience Center and National Institute of Neuroscience, University of Ferrara, via Fossato di Mortara 17-19, 44121 Ferrara, Italy.

T Leste-Lasserre (T)

INSERM, Neurocentre Magendie, U1215, Physiopathologie de la Plasticité Neuronale, F-33000 Bordeaux, France.

I Trigo Damas (IT)

HM CINAC, HM Puerta del Sur and CEU-San Pablo University Madrid, E-28938 Mostoles, Spain.
Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), Instituto Carlos III, Madrid, Spain.

M Goillandeau (M)

Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France.
CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France.

C Perier (C)

Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), Instituto Carlos III, Madrid, Spain.
Neurodegenerative Diseases Research Group, Vall d'Hebron Research Institute (VHIR)-Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), Barcelona, Spain.

C Estrada (C)

Clinical and Experimental Neuroscience Unit, School of Medicine, Biomedical Research Institute of Murcia (IMIB), University of Murcia, Campus Mare Nostrum, 30100 Murcia, Spain.
Institute of Research on Aging (IUIE), School of Medicine, University of Murcia, 30100 Murcia, Spain.

N Garcia-Carrillo (N)

Centro Experimental en Investigaciones Biomédica (CEIB), Universidad de Murcia, Murcia, Spain.

A Recasens (A)

Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), Instituto Carlos III, Madrid, Spain.
Neurodegenerative Diseases Research Group, Vall d'Hebron Research Institute (VHIR)-Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), Barcelona, Spain.

N N Vaikath (NN)

Neurological Disorders Research Center, Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Education City, Qatar.

O M A El-Agnaf (OMA)

Neurological Disorders Research Center, Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Education City, Qatar.

M T Herrero (MT)

Clinical and Experimental Neuroscience Unit, School of Medicine, Biomedical Research Institute of Murcia (IMIB), University of Murcia, Campus Mare Nostrum, 30100 Murcia, Spain.
Institute of Research on Aging (IUIE), School of Medicine, University of Murcia, 30100 Murcia, Spain.

P Derkinderen (P)

INSERM, U1235, Nantes F-44035, France.
Nantes University, Nantes F-44035, France.
CHU Nantes, Department of Neurology, Nantes F-44093, France.

M Vila (M)

Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), Instituto Carlos III, Madrid, Spain.
Neurodegenerative Diseases Research Group, Vall d'Hebron Research Institute (VHIR)-Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), Barcelona, Spain.
Department of Biochemistry and Molecular Biology, Autonomous University of Barcelona (UAB), Barcelona, Spain.
Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Spain.

J A Obeso (JA)

HM CINAC, HM Puerta del Sur and CEU-San Pablo University Madrid, E-28938 Mostoles, Spain.
Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), Instituto Carlos III, Madrid, Spain.

B Dehay (B)

Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France.
CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France.

E Bezard (E)

Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France.
CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH